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Mesotheliomas are primary cancers which develop within serosal
cavities, most often in the pleural cavity. Malignant mesothelioma
of the pleura is a rare cancer in the general population with an esti-
mated annual incidence of 750 cases. However, in certain indus-
trial regions there are more than 60 cases per million inhabitants.
In industrialized countries, mesothelioma is a tumour associated
with asbestos. An increased incidence (25% in 3 years) has been
seen since 1960, especially in older men. Because of the long
latent period between exposure and the development of the
disease, the peak incidence is expected to occur between the years
2010 and 2030. 
These recommendations were reviewed in May 1999. They will
be updated in 2001 or 2002 depending on the publication of new
data. 
DIAGNOSIS 
An occupational exposure to asbestos must be identified using a
standardized questionnaire to identify an occupational history
(standard). The assistance of a physician with expertise in occupa-
tional diseases can be requested (option). Previous exposure to
asbestos can be recognized if pleural plaques are found on thoracic
CT scan (although these are not always present).
In cases of doubt, where there is no clear history of exposure,
the diagnosis can be facilitated by searching and quantifying
asbestos bodies in various biological samples by light microscopy
(biometrology). Baseline values have been established to deter-
mine if a pulmonary asbestos burden is greater than that of the
general population (standard):
l greater than one asbestos body per sputum sample 
l greater than one asbestos body per millilitre of broncho-
alveolar lavage taken during fibroscopic bronchoscopy 
l greater than 1000 asbestos bodies per gram of dry pulmonary
tissue (in the case of surgical lung biopsy). 
The presence of asbestos bodies in smaller numbers does not
exclude the possibility of previous exposure to asbestos. Asbestos
fibres in broncho-alveolar lavage or lung tissue samples may be
quantified using electron microscopy (option). 
A thoracic CT scan is the standard examination to assess tumour
extent (and to evaluate response to treatment). To make a diag-
nosis of pleural mesothelioma, multiple biopsies (with at least 10
samples from multiple sites) of large size (greater or equal to
4 mm), including apparently healthy zones, must be taken at
thoracoscopy (standard). 
Exploration using video-assisted thoracoscopic surgery is an
alternative to thoracoscopy (option). Transparietal biopsy of a
solid mass and/or surgical biopsy should be reserved for cases
where there is a contra-indication to thoracoscopy and/or video-
scopic surgery (option). Surgical or video-assisted surgery is the
standard for differentiating a benign organizing pleuritis from a
malignant sarcomatoid mesothelioma. Frozen sections should not
be done routinely but may help to confirm the presence of diag-
nostic material. 
Immuno-histochemical studies must include as a minimum: 
l for epitheloid tumors, cytokeratin (CK 5/6), EMA, calretinin
Zymed and two or three negative glandular markers (CEA,
CD15, BeREP4...) 
l for spindle cell tumours: cytokeratin, vimentin, CD34. 
In cases of doubt, a histological diagnosis can be confirmed by
sending tissue and clinical samples to a panel of specialized
pathologists (French MESOPATH group). 
In the absence of clinical symptoms or signs, a search for metas-
tases is not useful (standard). 
CLASSIFICATION 
The classification system of the International Mesothelioma
Interest Group is currently best adapted to a combined medical-
surgical treatment approach, but must also be correlated with the
TNM classification of the International Union against Cancer
(UICC).
PROGNOSTIC FACTORS 
Three favourable prognostic factors most often identified in multi-
variate analyses are: 
l stage I or II disease (TNM or International Mesothelioma
Study Group) 
l epithelial histology 
l patient performance status 0 or 1. 
TREATMENT 
There is no standard treatment (Figure 1). The outcome depends
more on the prognostic factors for a given patient than the thera-
peutic modality chosen. 
Chest drain tracts and puncture sites must be routinely and
prophylactically irradiated (standard). 
Radical surgery as sole treatment has not been validated; it
should only be undertaken within a therapeutic study. 
Similarly, chemotherapy, immunotherapy alone, immuno-
therapy combined with chemotherapy or combined approaches
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considered within therapeutic trials. 
If intracavitary treatment is not planned (stages IA, IB), early
pleurodesis must be undertaken. 
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Therapeutic modalities
Standards
• there is no standard treatment as this is individualized on the basis 
  of prognostic factors
• routine prophylactic irradiation of drain sites
Option
the following should be done only within a clinical trial:
• radical surgery
• chemotherapy, immune therapy
• combination approaches (surgery, radiotherapy, 
   immunochemotherapy)
Recommendation
early pleurodesis is recommended if intracavitary treatment is not 
planned (stages IA,IB)
Figure 1 Treatment of malignant mesothelioma 